EP3725778

ASTELLAS PHARMA INC.
Application Number
EP20177837A
Filing Date
Sep 11, 2013
Status
Granted And Under Opposition
Jul 16, 2021
Grant Date
Aug 18, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3725778B1 was granted on Aug 18, 2021 by Astellas Pharma Inc. The patent is currently Granted And Under Opposition.

The table below shows 11 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCARE LTDMay 18, 2022ADMISSIBLE
ALFRED E. TIEFENBACHER (GMBH & CO. KG)May 18, 2022ADMISSIBLE
BULLE DR., JANMay 18, 2022ADMISSIBLE
ELKINGTON AND FIFE LLPMay 18, 2022ADMISSIBLE
HAMM&WITTKOPP PATENTANWALTE PARTMBBMay 18, 2022ADMISSIBLE
MAIWALD GMBHMay 18, 2022ADMISSIBLE
STADAMay 18, 2022ADMISSIBLE
SYNTHON BVMay 18, 2022ADMISSIBLE
DR. SCHON, NEYMEYR & PARTNER PATENTANWALTE MBBMay 17, 2022ADMISSIBLE
ZENTIVA K.S.May 13, 2022ADMISSIBLE
SANDOZMay 11, 2022ADMISSIBLE

The table below shows the patents of Astellas Pharma Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3791896Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerJan 10, 20243
EP3318259Stable Pharmaceutical Composition For Oral AdministrationJan 11, 20232
EP3725810Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerJul 6, 20222

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.